StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)

Close on Nov 17, 2026Market cap $254.77MP/E –Yield –

Evommune operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Evommune's operating income for the twelve months ending Sep 30, 2026 was -$121.89M. For fiscal 2025 it was -$81.07M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$81.07M–
FY2024Dec 31, 2024-$70.01M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$33.33M–
Q2 FY2026Jun 30, 2026-$34.90M–
Q1 FY2026Mar 31, 2026-$23.95M–
Q4 FY2025Dec 31, 2025-$29.72M–
Q3 FY2025Sep 30, 2025-$13.33M–
Q2 FY2025Jun 30, 2025-$22.99M–
Q1 FY2025Mar 31, 2025-$15.03M–
Q4 FY2024Dec 31, 2024-$21.45M–
Q3 FY2024Sep 30, 2024-$16.52M–

More Evommune figures

See a number that looks wrong?